A Phase 1 interventional study of Ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 18th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 1, and was the 13th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 28th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 1, and was the 19th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it. The study has two parts: A single-dose part and multiple-dose part. The single dose part of this study will last up to 24 weeks, including the screening period. The multiple dose part of this study will last up to 32 weeks including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
Drug: Ixekizumab
Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
Drug: Ixekizumab
Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
Drug: Ixekizumab
Administered as subcutaneous (SC) injection
Also known as: LY2439821
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)
Pharmacokinetics (PK): Cmax is the maximum observed concentration of Ixekizumab into serum.
Time frame: Single dose: Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141
Pharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) from time zero to infinity was reported.
Time frame: Predose, day 1, 3, 5, 8, 11, 15, 22, 29, 43, 57, 85, 113, 141
Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)
Pharmacokinetics: Cmax is the maximum observed concentration of Ixekizumab into serum.
Time frame: day 57 (pre-dose), 59, 61, 64, 67, 71, 78, 85, 99, 113, 141, 169, 197
Pharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)
Pharmacokinetics: Area under concentration of Ixekizumab from time Zero to 336h (AUC 0 to 336h) was reported (Multiple dose).
Time frame: day 57 (Pre-dose), 59, 61, 64, 67, 71
Pharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose)
Pharmacokinetics: Area under concentration of Ixekizumab from time zero to 672h (AUC 0 to 672h) was reported (Multiple dose).
Time frame: day 57 (Pre-dose), 59, 61, 64, 67, 71, 78, 85
All the re-enrolled participants from single dose period (SDP) to multiple dose period (MDP) have been washed out and screened for eligibility to MDP.
| Milestone | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|---|
| Started | 12 | 0 | 0 |
| Completed | 12 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|---|
| Started | 0 | 14 | 15 |
| Participants enrolled from single dose | 0 | 7 | 2 |
| Completed | 0 | 14 | 14 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
Pharmacokinetics (PK): Cmax is the maximum observed concentration of Ixekizumab into serum.
| Microgram per milliliter (ug/mL) | Ixekizumab Single Dose |
|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose) | 6.90 ± 43 |
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) from time zero to infinity was reported.
| Microgram*day per milliliter (ug*day/mL) | Ixekizumab Single Dose |
|---|---|
| Pharmacokinetics: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose) | 147 ± 48 |
Pharmacokinetics: Cmax is the maximum observed concentration of Ixekizumab into serum.
| Microgram per milliliter (ug/mL) | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose) | 19.9 ± 27 | 13.4 ± 32 |
Pharmacokinetics: Area under concentration of Ixekizumab from time Zero to 336h (AUC 0 to 336h) was reported (Multiple dose).
| Microgram*day per milliliter (ug*day/mL) | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|
| Pharmacokinetics: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose) | 224 ± 25 | 136 ± 31 |
Pharmacokinetics: Area under concentration of Ixekizumab from time zero to 672h (AUC 0 to 672h) was reported (Multiple dose).
| Microgram*day per milliliter (ug*day/mL) | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|
| Pharmacokinetics: Area Under Concentration From Time Zero to 672h (AUC 0 to 672h) of Ixekizumab (Multiple Dose) | 213 ± 29 |
Collected over Baseline to end of the study (up to 20 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab Single Dose | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Ixekizumab 80mg Q2W Multiple Dose | 0/14 (0%) | 1/14 (7.1%) | 11/14 (78.6%) |
| Ixekizumab 80mg Q4W Multiple Dose | 0/15 (0%) | 0/15 (0%) | 12/15 (80%) |
| Event | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/12 | 1/14 | 0/15 |
| CholecystitisHepatobiliary disorders | 0/12 | 1/14 | 0/15 |
| CholelithiasisHepatobiliary disorders | 0/12 | 1/14 | 0/15 |
| Event | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 5/12 | 6/14 | 2/15 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 5/14 | 3/15 |
| Protein urine presentInvestigations | 4/12 | 2/14 | 0/15 |
| FlatulenceGastrointestinal disorders | 3/12 | 0/14 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 3/14 | 2/15 |
| Electrocardiogram abnormalInvestigations | 1/12 | 3/14 | 2/15 |
| NasopharyngitisInfections and infestations | 2/12 | 1/14 | 1/15 |
| DizzinessNervous system disorders | 2/12 | 1/14 | 0/15 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/12 | 0/14 | 2/15 |
| UrticariaSkin and subcutaneous tissue disorders | 2/12 | 1/14 | 1/15 |
All the re-enrolled participants from SDP to MDP have been washed out and screened for eligibility to MDP.
| Age, Continuous(years) | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose | Total |
|---|---|---|---|---|
| Single Dose | 49.0 ± 12.1 | — | — | 49.0 ± 12.1 |
| Multiple Dose | — | 45.6 ± 12.5 | 45.5 ± 16.1 | 45.6 ± 14.2 |
| Sex: Female, Male(Participants) | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose | Total |
|---|---|---|---|---|
| Single Dose — Female | 2 | 0 | 0 | 2 |
| Single Dose — Male | 10 | 0 | 0 | 10 |
| Multiple Dose — Female | 0 | 3 | 5 | 8 |
| Multiple Dose — Male | 0 | 11 | 10 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose | Total |
|---|---|---|---|---|
| Single Dose Phase — Hispanic or Latino | 0 | 0 | 0 | 0 |
| Single Dose Phase — Not Hispanic or Latino | 12 | 0 | 0 | 12 |
| Single Dose Phase — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — Hispanic or Latino | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — Not Hispanic or Latino | 0 | 14 | 15 | 29 |
| Multiple Dose Phase — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose | Total |
|---|---|---|---|---|
| Single Dose Phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Single Dose Phase — Asian | 12 | 0 | 0 | 12 |
| Single Dose Phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Single Dose Phase — Black or African American | 0 | 0 | 0 | 0 |
| Single Dose Phase — White | 0 | 0 | 0 | 0 |
| Single Dose Phase — More than one race | 0 | 0 | 0 | 0 |
| Single Dose Phase — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — Asian | 0 | 14 | 15 | 29 |
| Multiple Dose Phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — Black or African American | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — White | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — More than one race | 0 | 0 | 0 | 0 |
| Multiple Dose Phase — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ixekizumab Single Dose | Ixekizumab 80mg Q2W Multiple Dose | Ixekizumab 80mg Q4W Multiple Dose | Total |
|---|---|---|---|---|
| China — Single Dose | 12 | 0 | 0 | 12 |
| China — Multiple Dose | 0 | 14 | 15 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in May 2019, 25 months.
Results were first posted in Jul 2020, 1 year 2 months after primary completion.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab